Patents by Inventor Kevin Roberg-Perez

Kevin Roberg-Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11920177
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: March 5, 2024
    Assignee: SASYA INC.
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20240035050
    Abstract: The present application discloses a microorganism engineered to express one or more enzymes which enhances the microorganism's ability to produce C2-4 alkene, and/or ethylene from C2-4 alkanol or thiol, optionally ethanol. The process of producing C2-4 alkanol and/or ethylene by the engineered microorganism is also discussed.
    Type: Application
    Filed: May 30, 2023
    Publication date: February 1, 2024
    Inventors: Tahereh KARIMI, Nymul KHAN, Davi Ludvig GONÇALVES, Kevin ROBERG-PEREZ
  • Publication number: 20230312253
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 5, 2023
    Applicant: CARGILL, INCORPORATED
    Inventors: Catherine Asleson DUNDON, Pirkko SUOMINEN, Aristos ARISTIDOU, Brian J. RUSH, Kari KOIVURANTA, Benjamin Matthew HAUSE, Thomas William McMULLIN, Kevin ROBERG-PEREZ
  • Patent number: 11691817
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: July 4, 2023
    Assignee: CARGILL, INCORPORATED
    Inventors: Catherine Asleson Dundon, Pirkko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Publication number: 20220325304
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20220315954
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 6, 2022
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20210155411
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: January 21, 2021
    Publication date: May 27, 2021
    Applicant: Cargill, Incorporated
    Inventors: Catherine Asleson DUNDON, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Patent number: 10899544
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 26, 2021
    Assignee: CARGILL, INCORPORATED
    Inventors: Catherine Asleson Dundon, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Publication number: 20200377302
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: March 30, 2018
    Publication date: December 3, 2020
    Applicant: Cargill Incorporated
    Inventors: Catherine Asleson Dundon, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Publication number: 20180257864
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: March 30, 2018
    Publication date: September 13, 2018
    Applicant: Cargill Incorporated
    Inventors: Catherine Asleson Dundon, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Publication number: 20150315616
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: May 25, 2015
    Publication date: November 5, 2015
    Inventors: Catherine Asleson Dundon, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Publication number: 20150259710
    Abstract: The present invention relates to recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise at least one nucleic acid molecule encoding a polypeptide with keto-isovalerate decarboxylase (KIVD) activity, wherein said polypeptide is at least about 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a polypeptide selected from SEQ ID NOs: 1-214. Also provided are modified decarboxylases exhibiting an improved ability to utilize ?-ketoisovalerate as a substrate in various beneficial enzymatic conversions.
    Type: Application
    Filed: July 30, 2012
    Publication date: September 17, 2015
    Applicant: Gevo, Inc.
    Inventors: Catherine Asleson Dundon, Kevin Roberg-Perez, Christopher Snow, Peter Meinhold
  • Publication number: 20120129230
    Abstract: Cells of the species Issatchenkia orientalis and closely related yeast species are transformed with a vector to introduce an exogenous lactate dehydrogenase gene. The cells produce lactic acid efficiently and are resistant at low pH, high lactate titer conditions.
    Type: Application
    Filed: December 9, 2011
    Publication date: May 24, 2012
    Inventors: Pirkko Suominen, Aristos Aristidou, Merja Penttila, Marja Ilmen, Laura Ruohonen, Kari Koivuranta, Kevin Roberg-Perez
  • Patent number: 8097448
    Abstract: Cells of the species Issatchenkia orientalis and closely related yeast species are transformed with a vector to introduce an exogenous lactate dehydrogenase gene. The cells produce lactic acid efficiently and are resistant at low pH, high lactate titer conditions.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: January 17, 2012
    Assignee: Cargill Inc.
    Inventors: Pirkko Suominen, Aristos Aristidou, Merja Pentilla, Marja Ilmen, Laura Ruohonen, Kari Koivuranta, Kevin Roberg-Perez
  • Publication number: 20090226989
    Abstract: Cells of the species Issatchenkia orientalis and closely related yeast species are transformed with a vector to introduce an exogenous lactate dehydrogenase gene. The cells produce lactic acid efficiently and are resistant at low pH, high lactate titer conditions.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 10, 2009
    Inventors: Pirkko Suominen, Aristos Aristidou, Merja Penttila, Marja Ilmen, Laura Ruohonen, Kari Koivuranta, Kevin Roberg-Perez
  • Publication number: 20090053782
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyueromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Application
    Filed: March 13, 2007
    Publication date: February 26, 2009
    Inventors: Catherine Asleson Dundon, Pirkko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez